Abstract:Introduction: The aim was to investigate the risk factors for recurrence after transurethral resection of bladder tumor (TURBT) in patients with non-muscle invasive bladder cancer (NMIBC) and to provide a basis for clinical prevention of recurrence of NMIBC. Methods: From January 2012 to December 2020, 592 patients with NMIBC who underwent TURBT attending the Second Affiliated Hospital of Xi’an Jiaotong University were retrospectively included in this study. Patients were divided into relapse and relapse-free groups according to whether relapse occurred within 2 years. Ultimately, 72 patients were included in the relapse group and 350 patients were included in the relapse-free group. Observation indicators included age, sex, smoking, underlying disease (hypertension, diabetes, coronary heart disease), two or more lesions, tumor size, hematuria, pathology grading (low, medium, high), staging (Ta, T1), muscular invasion in initial pathology, tumor base (sessile, pedunculated), use of intravesical drug (pirarubicin, bacillus Calmette-Guerin [BCG], mitomycin, hydroxycamptothecin, gemcitabine). Results: In this study, the 2-year recurrence rate of NMIBC patients after TURBT was 17.06%. There were significant differences in comparison of pirarubicin, BCG, and mitomycin treatment between the two groups ( p < 0.05). To avoid missing risk factors for recurrence, factors with p < 0.1 were analyzed. The results of univariate logistic regression analysis showed that NMIBC patients with BCG treatment (OR = 5.088, 95% CI = 1.444–17.73, p = 0.012), high pathology grading (OR = 0.415, 95% CI = 0.197–0.880, p = 0.023), T1 stage (OR = 2.097, 95% CI = 0.996–4.618, p = 0.059), mitomycin treatment (OR = 5.029, 95% CI = 1.149–21.77, p = 0.031), and pirarubicin treatment (OR = 1.794, 95% CI = 1.079–3.030, p = 0.024) had significantly higher risk of recurrence within 2 years after TURBT. The results of multivariate logistic regression analysis showed that NMIBC patients with high pathology grading (OR = 0.4030, 95% CI = 0.1702–0.8426, p = 0.0241), pirarubicin treatment (OR = 1.961, 95% CI = 1.159–3.348, p = 0.0125), and BCG treatment (OR = 6.201, 95% CI = 1.275–29.73, p = 0.0190) had significantly higher risk of recurrence within 2 years after TURBT. Conclusion: Our study highlights the importance of postoperative surveillance and individualized treatment for patients with NMIBC. Our findings show that high pathology grading, pirarubicin treatment, and BCG treatment are independent risk factors for recurrence after TURBT in patients with NMIBC. However, caution is warranted when interpreting our findings due to the small sample size and the need for further research to confirm the negative impact of mitomycin and BCG on recurrence rates.

Can a Second Resection Be Avoided after Initial Thulium Laser Endoscopic En Bloc Resection for Non-Muscle Invasive Bladder Cancer? A Retrospective Single-Center Study of 251 Patients

Combined Modality Therapy Following Bladder Conservation Surgery for Bladder Cancers

Comparison between 2-μm Continuous-wave Thulium Laser and Transurethral Resection for Non-muscle-invasive Bladder Cancer: A Retrospective Comparative Study

Thulium laser en bloc resection reduces recurrence rates in NMIBC patients with tumor diameters ≥3cm compared to transurethral resection: a non-randomized controlled study

Initial experience of flexible ureteroscopy combined with thulium laser for the treatment of upper urinary tract urothelial carcinoma

The metabolic alterations of immobilization, injury and paraplegia. I. Protein metabolism.

Differences in oncological benefits from second transurethral resection between white‐light initial surgery and photodynamic diagnosis‐guided initial surgery for primary high‐risk non‐muscle invasive bladder cancer

Analysis of Risk Factors for Recurrence after Transurethral Resection of Bladder Tumor in Patients with Non-Muscle Invasive Bladder Cancer: 2-Year Follow-Up Outcomes

Treatment and management of high-grade T1 bladder cancer: what should we do after second TUR?

Nonprescription Ibuprofen: Side Effect Profile

[Repeat Transurethral Resection for Non-Muscle Invasive Bladder Cancer].

An evaluation to define the role of repeat transurethral resection in a treatment algorithm for non-muscle-invasive bladder cancer

Prognostic significance of residual tumor at restaging transurethral bladder resection in high-risk non-muscle-invasive bladder cancer

Development of a dynamic risk system for predicting the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer after thulium laser resection of bladder tumor or transurethral resection of bladder tumor followed by intravesical BCG instillation

Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients

Comparative Study of 2 Um Laser Versus Holmium Laser for the Resection of Non-Muscle Invasive Bladder Cancer

XXVII Effects of Nicotine on Ciliary Activity in Vitro

Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial

Clinical significance of antiphosphatidylethanolamine antibodies in the so-called "seronegative antiphospholipid syndrome".

A rare huge bladder inflammatory myofibroblastic tumor treated by en bloc resection with diode laser: a case report and literature review

An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial